ALNY Looks 55.6% Undervalued on GF Value™ Amid New Cardiovascular RNAi Data

gurufocus.com · 2026-08-30

On August 30, 2026, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) unveiled promising clinical results at the European Society of Cardiology Congress 2026, reinforc

TickrTrends take: Alnylam Pharmaceuticals trades with significant undervaluation according to GF Value analysis, suggesting the market may not fully reflect the company's potential in cardiovascular applications through its RNAi technology platform. TickrTrends currently awaits a complete valuation assessment for the Healthcare sector company, meaning investors focused on valuation metrics should monitor how new cardiovascular data influences the company's earnings trajectory and competitive positioning. The gap between current market pricing and fundamental value estimates could shift materially as clinical and commercial progress in this therapeutic area becomes clearer to the market.

Read the full story at gurufocus.com →